Harold W. Werner

Studies on Estrogen Tri-p-anisylchloroethylene:

Summary The pharmacology of Tace (tri-p-anisylchloroethylene), a new compound with estrogenic activity, differs in important respects from that of hexestrol which is typical of the natural and better known synthetic estrogens: (1) Tace does not cause and hexestrol does cause pituitary enlargement in rats; (2) Tace has a lesser but similar effect to hexestrol on organs in which the action of the two compounds is mediated through the pituitary; (3) fat storage resulting in long activity occurs following oral administration of large doses of Tace, while there is no fat storage and action is short following hexestrol administration; (4) estrogenic material equivalent in biologic potency to more than the administered dose of Tace is eliminated with the feces, while only small amounts of estrogenic material are eliminated following hexestrol administration.

Fat Stsorage of an Estrogen in Women Following Orally Administered tri-p-anisylchloroethylene

Summary The repeated oral administration of TACE to human subjects results in storage of considerable amounts of estrogenic material in the body fat. This material remains in the fat for prolonged periods following cessation of TACE therapy. Results of studies in a limited number of cases suggest that both duration of therapy and the size of the doses are contributing factors governing the level of estrogenic material in the fat.